Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Protein subunit |
Clinical data | |
Routes of administration | Intramuscular |
Noora (Persian: نورا) is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. (lit. White Cypress Plasma Treatment) in Iran.[1][2]
It requires three doses given by intramuscular injection on days 0, 21 and 35.[3]
Noora is a recombinant RBD protein subunit vaccine.[3]
Up to 8 December 2021, 5 millions doses have been produced.[4]
Phase | Registration number | Start | Number of participants | Age of participants | Ref | ||
---|---|---|---|---|---|---|---|
Total | Vaccine | Placebo | |||||
I | IRCT20210620051639N1 | 25 June 2021 | 70 | 30(80 μg)
30(120 μg) |
10(placebo) | 18–50 years | [3] |
II | IRCT20210620051639N2 | 10 October 2021 | 300 | 240 | 60 | 18–40 years | [5] |
III | IRCT20210620051639N3 | 23 December 2021 | 10000 | >18 years | [6] |
| |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Development |
| ||||||||||
Classes |
| ||||||||||
Administration |
| ||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers |
| ||||||||||
Controversy |
| ||||||||||
Related |
| ||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This article about vaccinesorvaccination is a stub. You can help Wikipedia by expanding it. |